Pune, India, June 2019, MRFR Press Release/- Market Research Future has Published a Cooked Research Report on the Global Human Milk Oligosaccharides Market.
The Global Human Milk Oligosaccharides Market is Expected to Register a CAGR of 27.06% During the Forecast Period with a market value of USD 110.03 Million in 2018.
The role of breast milk in infant nutrition is of paramount importance as it ensures health and nourishment. However, in many cases, breastfeeding is not an option due to factors such as genetic defects, terminal diseases, and infections. In such cases, HMOs and associated functional foods play an important role in providing the required nutrition and immunity. HMOs play a major role in ensuring immunity more than nourishment. They are undigested and thus act as preferred feed for the good bacteria in the gut. This boosts the immune system, especially in infants, which helps fight viruses and infectious bacteria.
The global human milk oligosaccharides market is segmented on the basis of type, application, and region.
Based on type, the global human milk oligosaccharides market has been segregated into neutral and acidic. Application-wise, the market has been segmented into food industry and laboratory research.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/human-milk-oligosaccharides-market-7843
Market Research Future (MRFR) recognizes DuPont Nutrition & Health (Denmark), Abbott (US), BASF SE (Germany), Glycom (Denmark), Dextra Laboratories Limited (UK), Elicityl S.A. (France), Glycosyn LLC (US), Inbiose (Belgium), Jennewein Biotechnologie GmbH (Germany), Medolac Laboratories (US), Nestlé Health Science (Switzerland), and ZuChem (US) as the key players in the global human milk oligosaccharides market.
The global human milk oligosaccharides market has been segmented, on the basis of region, into North America, Europe, China, and Japan.
North America accounted for the largest share of the global human milk oligosaccharides market in 2018 and is expected to maintain its dominance throughout the forecast period. This can be attributed to the high consumption of infant formula in the region and increasing approval of new HMO products.
The European human milk oligosaccharides market was the second largest in 2018. In the UK, the rate of breastfeeding is the lowest in the world, which is a major determinant driving the regional market growth. Moreover, the approval of new and enhanced HMOs in the region is also contributing to the growth of the European human milk oligosaccharides market.
China is expected to be the fastest-growing market for HMOs during the forecast period owing to the increasing demand for HMO-based infant formula in the country.
Key Findings of the Study